Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (421-430 of 441) with videos related to

Pageof 45
Sort By:
Gut|August 1, 2014
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised studyChristophe Hézode, Gideon M Hirschfield, Wayne Ghesquiere, et al.
Journal of Viral Hepatitis|November 1, 2018
Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohortSegolene Brichler, Pierre Nahon, Fabien Zoulim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 5, 2022
Securing wider EU commitment to the elimination of hepatitis C virusHeiner Wedemeyer, Tammo L Tergast, Jeffrey V Lazarus, et al.
Gastroenterology|July 22, 2018
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance ProgramsPierre Nahon, Richard Layese, Valérie Bourcier, et al.
Journal of Hepatology|July 3, 2020
Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV statusEtienne Audureau, Fabrice Carrat, Richard Layese, et al.
Hepatology (Baltimore, Md.)|June 28, 2016
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)Nathalie Ganne-Carrié, Richard Layese, Valérie Bourcier, et al.
Gastroenterology|April 8, 2014
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosisChristophe Hézode, Helene Fontaine, Celine Dorival, et al.
Hepatology (Baltimore, Md.)|February 14, 2015
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)Jean-Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, et al.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
Gastroenterology|May 6, 2018
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort StudyCharlotte E Costentin, Richard Layese, Valérie Bourcier, et al.
Pageof 45

Showing results (421-430 of 441) with videos related to

Sort By:
Pageof 45
Gut|August 1, 2014
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised studyChristophe Hézode, Gideon M Hirschfield, Wayne Ghesquiere, et al.
Journal of Viral Hepatitis|November 1, 2018
Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohortSegolene Brichler, Pierre Nahon, Fabien Zoulim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 5, 2022
Securing wider EU commitment to the elimination of hepatitis C virusHeiner Wedemeyer, Tammo L Tergast, Jeffrey V Lazarus, et al.
Gastroenterology|July 22, 2018
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance ProgramsPierre Nahon, Richard Layese, Valérie Bourcier, et al.
Journal of Hepatology|July 3, 2020
Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV statusEtienne Audureau, Fabrice Carrat, Richard Layese, et al.
Hepatology (Baltimore, Md.)|June 28, 2016
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)Nathalie Ganne-Carrié, Richard Layese, Valérie Bourcier, et al.
Gastroenterology|April 8, 2014
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosisChristophe Hézode, Helene Fontaine, Celine Dorival, et al.
Hepatology (Baltimore, Md.)|February 14, 2015
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)Jean-Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, et al.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
Gastroenterology|May 6, 2018
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort StudyCharlotte E Costentin, Richard Layese, Valérie Bourcier, et al.
Pageof 45